RenovoRx, Inc.
Close on Oct 19, 2026
- Market cap
- $54.87M
- P/E (TTM)
- –
- Dividend yield
- –
About RenovoRx
Surgical & Medical Instruments & Apparatus, SIC 3841
RenovoRx, Inc. is a commercial-stage life sciences company that develops targeted oncology therapies and commercializes local drug-delivery medical devices. The company's core offering centers on its patented Trans-Arterial Micro-Perfusion therapy platform, enabled by its FDA-cleared RenovoCath catheter. This device delivers chemotherapeutic agents across arterial walls directly into solid tumors to bathe target tissue and minimize systemic toxicity. RenovoRx also investigates drug-device combination candidates, including intra-arterial gemcitabine delivery for locally advanced pancreatic cancer and bile duct cancer. Its primary customers include cancer treatment centers, hospitals, and high-volume National Cancer Institute-designated institutions.
The company focuses its commercialization activities in the United States, targeting high-volume treatment centers across the country. Commercial adoption includes 12 active cancer centers using its device, with an additional 21 centers evaluating or preparing for activation, totaling 33 institutions in its customer pipeline. RenovoRx maintains its principal executive offices and headquarters in Mountain View, California.
Summary of the business section of RenovoRx's latest annual report, written by StockData.
Company profile
Company
- Legal name
- RenovoRx, Inc.
- Headquarters
- Mountain View, CA
- Address
- 2570 W. El Camino Real, Ste. 320, 94040
- Phone
- (408) 800-2649
- Employees
- 17, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Frank, Rimerman + Co. LLP, San Francisco, California
Stock & identifiers
- Ticker
- RNXT
- Exchange
- Nasdaq
- IPO date
- Aug 27, 2021
- Shares outstanding
- 45M, Aug 7, 2026
- Public float
- $26.60M, Jun 30, 2024
- Filer category
- <br>Emerging growth company
- SEC CIK
- 1574094
- CUSIP
- 75989R107
- ISIN
- US75989R1077
- EIN
- 27-1448452
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Ramtin Agah | Chief Medical Officer, Director | 1,773,460 |
| Shaun Bagai | Chief Executive Officer, Director | 364,340 |
| Mark Voll | Chief Financial Officer | 319,580 |
| Leesa Gentry | Chief Clinical Officer | – |
| Ron Kocak | VP, Controller and PAO | 12,595 |
| Una S. Ryan | Director | 80,959 |
| Laurence Marton | Director | 75,884 |
| K. Angela Macfarlane | Director | 40,983 |
| Robert J. Spiegel | Director | 40,983 |
Employees
Headcount reported in annual reports
“We are a small company with 17 employees as of December 31, 2025.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Jul 2, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Jan 2, 2026 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Mar 31, 2025 | Late filing | Notification of late filing |
| Aug 16, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| May 3, 2024 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Feb 23, 2024 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 25, 2023 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Aug 15, 2023 | Late filing | Notification of late filing |
| Dec 10, 2021 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Aug 27, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Aug 11, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |